Unlocking R&D Tax Credit Opportunities in the Pharmaceutical Industry

< Back to insights

• R&D activities do not need to result in a successful outcome to qualify. Iterative and unsuccessful experimentation may still meet the requirements of IRC §41.
• With thoughtful scoping and experienced guidance, pharmaceutical companies can identify, substantiate, and sustain significant R&D tax credit benefits.

Rethinking R&D in the Pharmaceutical Industry

The pharmaceutical industry is constantly evolving, driven by scientific advancement, regulatory demands, and the need to improve product performance, safety, and manufacturability, making technical problem‑solving and experimentation an inherent part of day‑to‑day operations. While many organizations recognize that early-stage pharmaceutical discovery may qualify for R&D tax credit opportunities, the full scope of eligible activities is often underestimated.

In practice, qualifying research frequently continues well beyond what is traditionally labeled as “R&D.” Activities such as formulation development, analytical method trials, and manufacturing process optimization often involve substantial technical uncertainty and experimentation, precisely the type of work Congress intended to encourage under Internal Revenue Code §41.

Understanding how these activities align with the R&D tax credit framework is essential to capturing available benefits confidently and defensibly.

Qualifying for the R&D Tax Credit and Identifying Technical Uncertainty

To qualify for the R&D tax credit, activities must be undertaken to resolve technical uncertainty through a process of experimentation. In the pharmaceutical industry, this uncertainty often arises across multiple dimensions, including, but not limited to:

• Scientific uncertainty: Determining whether a compound can achieve stability, efficacy, or bioavailability within a given formulation or delivery system.
• Design uncertainty: Evaluating alternative formulations, dosage forms, or manufacturing approaches to meet performance and quality targets.
• Methodological uncertainty: Developing or refining analytical methods, assays, validation techniques, or testing protocols capable of producing reliable results.

These challenges are typically addressed through hypothesis-driven experimentation, iterative testing, and data analysis, all hallmarks of qualifying research under IRC §41.

It is also important to highlight specifically excluded activities under IRC §41. While pharmaceutical R&D encompasses a broad range of qualifying work, certain activities like routine quality control testing, commercial manufacturing, and post‑approval regulatory maintenance are generally excluded.

R&D Across the Pharmaceutical Development Lifecycle

While it may seem intuitive that R&D activity ends once a formulation is finalized, pharmaceutical development rarely follows a straight line. Qualifying R&D activities often continue throughout subsequent stages of product development, including, but not limited to:

• Preclinical and Early Development: Compound screening, formulation feasibility trials, and proof-of-concept testing often involve evaluating alternative techniques to resolve scientific uncertainty.
• Formulation and Process Development: As development advances, companies frequently conduct iterative formulation optimization, stability studies, and analytical method enhancements focused on manufacturability, performance, and shelf life.
• Manufacturing Scale-Up and Optimization: Even after a viable formulation is identified, significant uncertainty may remain around scaling, reproducibility, and process control. Efforts to optimize production methods and ensure consistent quality commonly involve experimentation that may qualify for R&D credit opportunities.

In summary, qualifying R&D activities can occur even when a product concept is already defined or commercially viable.

The Importance of Proper Business Component Scoping

Correctly identifying business components is a foundational aspect of a defensible R&D tax credit claim and is especially critical in the pharmaceutical industry.

Under IRC §41, a business component may include a product or a process, and qualification must be evaluated separately for each component. In practice, pharmaceutical R&D often spans both:

• Product-focused components, such as product compounds, formulations, dosage forms, or delivery systems.
• Process-focused components, including manufacturing methods, scale-up techniques, formulation processes, and analytical or quality control methodologies.

Treasury Regulations and court decisions make clear that manufacturing and production processes must be evaluated independently from the products themselves. When this scoping is performed thoughtfully, not only does it strengthen substantiation and reduce audit risk, but it often uncovers additional qualifying activities that may otherwise be overlooked.

Why Experienced Guidance Matters

Identifying and sustaining R&D tax credits in the pharmaceutical industry requires more than technical knowledge, it demands a deep understanding of how scientific activities intersect with tax law, documentation standards, and evolving compliance requirements.

Recent regulatory developments and increased scrutiny highlight the importance of contemporaneous documentation that ties employee activities and expenditures directly to identifiable technical uncertainties and experimentation efforts. At Bennett Thrasher, our professionals bring a comprehensive understanding of pharmaceutical development processes and the R&D tax credit framework, allowing us to help companies identify overlooked opportunities, strengthen substantiation, and confidently claim and maximize the incentives they have earned.

Final Thoughts

For pharmaceutical companies, R&D tax credits represent a meaningful opportunity, not just to reduce tax liability, but to reinvest in innovation. With the right approach and experienced advisors, companies can move beyond common misconceptions, capture the full value of their qualifying activities, and do so in a way that is accurate, defensible, and sustainable.

For more than four decades, Bennett Thrasher has provided businesses and individuals with strategic business guidance and solutions through professional tax, audit, advisory, and business process outsourcing services. Contact Nina Desai, Partner in Bennett Thrasher’s Credits & Incentives practice, to learn more about how Bennett Thrasher can support your R&D tax credit strategy, or call us at 770.396.2200.

Frequently Asked Questions

Do pharmaceutical R&D activities need to be successful to qualify for the R&D tax credit?    

No. Qualification is based on the process, not the outcome. Hypothesis-driven experimentation performed to resolve technical uncertainty may qualify under IRC §41. Oftentimes, efforts that are iterative, unsuccessful, or ultimately abandoned highlight core R&D efforts.

Are R&D tax credits limited to early-stage compound discovery or formal R&D departments?

No. Qualifying R&D may occur throughout the pharmaceutical product development lifecycle and is not limited to early-stage discovery activities. Employees outside of traditional R&D functions, such as manufacturing, quality, or technical operations, may perform qualifying research when their efforts are grounded in technical science and focus on resolving technical uncertainty.

Can pharmaceutical companies claim both federal and state R&D tax credits?    

Yes. In addition to the federal R&D tax credit, many states offer their own R&D incentives. Evaluating federal and state credits together can help pharmaceutical companies ensure qualifying activities and expenses are fully captured across jurisdictions.

Back to insights